- Previous Close
1.2200 - Open
1.3120 - Bid 1.3220 x --
- Ask 1.3660 x --
- Day's Range
1.3120 - 1.3120 - 52 Week Range
0.5770 - 2.1350 - Volume
1,500 - Avg. Volume
351 - Market Cap (intraday)
182.712M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1900 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.75
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
www.atossatherapeutics.comRecent News: YAG2.F
View MorePerformance Overview: YAG2.F
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YAG2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YAG2.F
View MoreValuation Measures
Market Cap
169.90M
Enterprise Value
98.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.68%
Return on Equity (ttm)
-28.00%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.91M
Diluted EPS (ttm)
-0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
79.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.24M